EPS for QIAGEN N.V. (QGEN) Expected At $0.34

October 13, 2018 - By Vivian Park


Analysts expect QIAGEN N.V. (NYSE:QGEN) to report $0.34 EPS on November, 5.They anticipate $0.02 EPS change or 6.25 % from last quarter’s $0.32 EPS. QGEN’s profit would be $77.19M giving it 25.26 P/E if the $0.34 EPS is correct. After having $0.33 EPS previously, QIAGEN N.V.’s analysts see 3.03 % EPS growth. The stock increased 1.06% or $0.36 during the last trading session, reaching $34.36. About 1.11 million shares traded or 20.80% up from the average. QIAGEN N.V. (NYSE:QGEN) has risen 18.00% since October 13, 2017 and is uptrending. It has outperformed by 2.38% the S&P500.

QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company has market cap of $7.80 billion. It offers sample technologies for plasmid deoxyribonucleic acid purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, and library preparation for sequencing applications; and assay technology solutions. It has a 104.12 P/E ratio. The firm provides Ingenuity Variant Analysis, a cloud platform that interprets data from next-generation sequencing (NGS) analysis; QIAGEN Clinical Insight, an evidence decision support solution; CLC Genomics Workbench for the analysis and visualization of data from various NGS platforms; and GeneGlobe, a Web portal that enables researchers to search and select gene-and pathway-specific solutions from pre-designed and custom PCR assay kits, NGS assay panels, and other products.

QIAGEN N.V. (NYSE:QGEN) Ratings Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.